Clinical trial
Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV…
NCT00091156 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Terminated
Key facts
| NCT number | NCT00091156 |
|---|---|
| Title | Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer |
| Official title | A Randomized Phase III Study of Follow Up With or Without Adjuvant Gefitinib (Iressa™) Following Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug, Procedure |
| Interventions | gefitinib, adjuvant therapy |
| Enrollment | 598 |
| Start date | May 1, 2004 |
| Primary completion | Jul 1, 2008 |
| First posted | Sep 8, 2004 |
| Last update posted | Jul 16, 2012 |
| Countries | Belgium, Cyprus, Egypt, Italy, Netherlands |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: